David Snipelisky1, Jacob Kelly1, James A Levine1, Gabriel A Koepp1, Kevin J Anstrom1, Steven E McNulty1, Rosita Zakeri1, G Michael Felker1, Adrian F Hernandez1, Eugene Braunwald1, Margaret M Redfield2. 1. From the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (D.S., R.Z., M.M.R.); Duke Clinical Research Institution, Duke University, Durham, NC (J.K., K.J.A., S.E.M., G.M.F., A.F.H.); Endocrine Research Unit, Mayo Clinic, Phoenix, AZ (J.A.L., G.A.K.); and Brigham and Women's Hospital, Boston, MA (E.B.). 2. From the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (D.S., R.Z., M.M.R.); Duke Clinical Research Institution, Duke University, Durham, NC (J.K., K.J.A., S.E.M., G.M.F., A.F.H.); Endocrine Research Unit, Mayo Clinic, Phoenix, AZ (J.A.L., G.A.K.); and Brigham and Women's Hospital, Boston, MA (E.B.). redfield.margaret@mayo.edu.
Abstract
BACKGROUND: Daily physical activity assessed by accelerometers represents a novel method to assess the impact of interventions on heart failure (HF) patients' functional status. We hypothesized that daily activity varies by patient characteristics and correlates with established measures of HF severity in HF with preserved ejection fraction. METHODS AND RESULTS: In this ancillary study of the NEAT-HFpEF trial (Nitrate's Effects on Activity Tolerance in HF With Preserved Ejection Fraction), average daily accelerometer units (ADAU) and hours active per day were assessed during a 14-day period before starting isosorbide mononitrate or placebo (n=110). Baseline ADAU was negatively associated with age, female sex, height, and body mass index, and these variables accounted for 28% of the variability in ADAU (P<0.007 for all). Adjusting for these factors, patients with lower ADAU were more likely to have had an HF hospitalization, orthopnea, diabetes mellitus and anemia, be treated with β-blockers, have higher ejection fraction, relative wall thickness and left atrial volume, and worse New York Heart Association class, HF-specific quality of life scores, 6-minute walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all). Associations between hours active per day and clinical characteristics were similar. Relative to baseline, there were no significant associations between changes in ADAU or hours active per day and changes in standard functional assessments (New York Heart Association, quality of life, 6-minute walk distance, and NT-proBNP) with isosorbide mononitrate. CONCLUSIONS: Daily activity is a measure of HF-related and global functional status in HF with preserved ejection fraction. As compared with intermittently assessed standard HF assessments, change in daily activity may provide unique information about the impact of HF interventions on functional status. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02053493.
RCT Entities:
BACKGROUND: Daily physical activity assessed by accelerometers represents a novel method to assess the impact of interventions on heart failure (HF) patients' functional status. We hypothesized that daily activity varies by patient characteristics and correlates with established measures of HF severity in HF with preserved ejection fraction. METHODS AND RESULTS: In this ancillary study of the NEAT-HFpEF trial (Nitrate's Effects on Activity Tolerance in HF With Preserved Ejection Fraction), average daily accelerometer units (ADAU) and hours active per day were assessed during a 14-day period before starting isosorbide mononitrate or placebo (n=110). Baseline ADAU was negatively associated with age, female sex, height, and body mass index, and these variables accounted for 28% of the variability in ADAU (P<0.007 for all). Adjusting for these factors, patients with lower ADAU were more likely to have had an HF hospitalization, orthopnea, diabetes mellitus and anemia, be treated with β-blockers, have higher ejection fraction, relative wall thickness and left atrial volume, and worse New York Heart Association class, HF-specific quality of life scores, 6-minute walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all). Associations between hours active per day and clinical characteristics were similar. Relative to baseline, there were no significant associations between changes in ADAU or hours active per day and changes in standard functional assessments (New York Heart Association, quality of life, 6-minute walk distance, and NT-proBNP) with isosorbide mononitrate. CONCLUSIONS: Daily activity is a measure of HF-related and global functional status in HF with preserved ejection fraction. As compared with intermittently assessed standard HF assessments, change in daily activity may provide unique information about the impact of HF interventions on functional status. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02053493.
Authors: Ann M Harris; Lorraine M Lanningham-Foster; Shelly K McCrady; James A Levine Journal: Am J Physiol Endocrinol Metab Date: 2007-04 Impact factor: 4.310
Authors: Miles D Witham; Ishbel S Argo; Derek W Johnston; Allan D Struthers; Marion E T McMurdo Journal: Eur J Heart Fail Date: 2005-07-25 Impact factor: 15.534
Authors: Martha E Billings; Dayna A Johnson; Guido Simonelli; Kari Moore; Sanjay R Patel; Ana V Diez Roux; Susan Redline Journal: Chest Date: 2016-06-18 Impact factor: 9.410
Authors: Michael L Alosco; Mary Beth Spitznagel; Lindsay Miller; Naftali Raz; Ronald Cohen; Lawrence H Sweet; Lisa H Colbert; Richard Josephson; Donna Waechter; Joel Hughes; Jim Rosneck; John Gunstad Journal: Health Psychol Date: 2012-08-27 Impact factor: 4.267
Authors: Brian R Lindman; Victor G Dávila-Román; Douglas L Mann; Steven McNulty; Marc J Semigran; Gregory D Lewis; Lisa de las Fuentes; Susan M Joseph; Justin Vader; Adrian F Hernandez; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2014-08-12 Impact factor: 24.094
Authors: Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor Journal: Circulation Date: 2018-09-04 Impact factor: 29.690
Authors: Chares A German; Peter H Brubaker; M Benjamin Nelson; Jason Fanning; Fan Ye; Dalane W Kitzman Journal: J Card Fail Date: 2021-06 Impact factor: 6.592
Authors: Garrett Ash; Sangchoon Jeon; Samantha Conley; Andrea K Knies; Henry K Yaggi; Daniel Jacoby; Christopher S Hollenbeak; Sarah Linsky; Meghan O'Connell; Nancy S Redeker Journal: Behav Sleep Med Date: 2020-10-13 Impact factor: 3.492
Authors: Ellora Sen-Gupta; Donald E Wright; James W Caccese; John A Wright; Elise Jortberg; Viprali Bhatkar; Melissa Ceruolo; Roozbeh Ghaffari; Dennis L Clason; James P Maynard; Arthur H Combs Journal: Digit Biomark Date: 2019-03-01